- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Aurora, Colorado + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dexamethasone, Echocardiography, Elotuzumab, Magnetic Resonance Imaging, Mezigdomide, X-Ray Imaging
- Procedure · Drug · Biological
- Lead sponsor
- Abdullah Khan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
- Interventions
- AZD0466
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more
- Conditions
- Hodgkin's Lymphomas
- Interventions
- MDX-1401
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York + 3 more
- Conditions
- Lymphoma
- Interventions
- itacitinib, ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Long Beach, California + 18 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Lenalidomide
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Los Angeles, California • Redondo Beach, California + 7 more
- Conditions
- Central Nervous System Neoplasms, Neoplasm Metastasis
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
- Interventions
- BST-236
- Drug
- Lead sponsor
- BioSight Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Shreveport, Louisiana • Houston, Texas • Charlottesville, Virginia + 1 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- Our Lady of Mercy Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, cyclophosphamide, melphalan, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2001
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Teclistamab
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 10 more
- Conditions
- Precursor Cell Lymphoblastic Leukemia-lymphoma
- Interventions
- Ixazomib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Jackson, Mississippi • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
- Interventions
- Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Talquetamab, Mezigdomide, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed/Refractory Mantle Cell Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Palo Alto, California • Santa Monica, California + 19 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- asparaginase, cytarabine, gemtuzumab ozogamicin, mitoxantrone hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Lenalidomide, nab-paclitaxel
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Everolimus, rituximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- flow cytometry, laboratory biomarker analysis, Data Collection
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Myeloid Leukemia
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more